CSF3 and breast carcinoma: However, findings from this study provide an initial insight into how common these complications are in our environment and provide preliminary evidence to guide routine clinical use of prophylactic G-CSF at the initiation of breast cancer chemotherapy, particularly in at-risk groups as identified in this study and others.